Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still less than its injectable competitors.

Lilly’s stock was down more than 14 percent on the day after the results were announced.

After 72 weeks, patients taking the highest dose of the drug, called orforglipron, lost an average of 12.4 percent of their weight, or 27.3 pounds, in a 72-week trial.

When analyzing all participants regardless of discontinuations, patients experienced weight loss of 11.2 percent.

While promising, the results are not as strong as the two injectable drugs already on the market.

Orforglipron has not been directly compared with Wegovy or Zepbound, but trials of Novo Nordis

See Full Page